10-Q: Seer Inc. Reports Second Quarter 2024 Financial Results, Revenue Declines Amidst Strategic Realignment

Seer Inc. reported a decrease in revenue for the second quarter of 2024, alongside a net loss, as the company continues its commercialization efforts and strategic realignment.

Summary

• Seer Inc. reported a total revenue of $3.07 million for the three months ended June 30, 2024, a decrease of 23% compared to the same period in 2023.
• The company's product revenue increased slightly to $1.76 million, while service revenue rose to $0.68 million.
• Related party revenue decreased significantly to $0.58 million, and grant and other revenue also saw a substantial decrease to $0.05 million.
• The cost of revenue decreased by 22% to $1.34 million, primarily due to lower product revenue from fewer instrument sales.
• Operating expenses decreased by 5% to $28.83 million, with research and development expenses down by 10% and selling, general, and administrative expenses remaining flat.
• The company reported a net loss of $22.85 million for the quarter, compared to a net loss of $23.43 million in the same period last year.
• For the six months ended June 30, 2024, total revenue was $6.14 million, a decrease of 24% compared to the same period in 2023.
• The net loss for the six months ended June 30, 2024, was $43.53 million, compared to a net loss of $47.39 million in the same period last year.
• As of June 30, 2024, Seer had cash, cash equivalents, and investments of $344.6 million and an accumulated deficit of $349.3 million.
• The company believes its current cash and investments are sufficient to fund operations for at least the next twelve months.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are some positive aspects, such as the decrease in operating expenses and the company's strong cash position, the significant decrease in revenue and continued net losses are concerning. The company is still in the early stages of commercialization and faces significant risks, which tempers the overall sentiment.

Positives

• Service revenue increased by 46% in Q2 2024, indicating growth in this area of the business.
• Cost of revenue decreased by 22% in Q2 2024, suggesting improved efficiency in production or service delivery.
• Research and development expenses decreased by 10% in Q2 2024, potentially reflecting a more focused approach to R&D.
• The net loss decreased slightly in both Q2 2024 and the first six months of 2024 compared to the same periods in 2023.
• The company has a substantial amount of cash and investments, which it believes is sufficient to fund operations for at least the next twelve months.

Negatives

• Total revenue decreased by 23% in Q2 2024 and 24% for the first six months of 2024, indicating a significant decline in sales.
• Related party revenue decreased significantly, suggesting a potential risk in relying on this revenue stream.
• Grant and other revenue decreased substantially, indicating a reduction in funding from these sources.
• The company continues to incur significant net losses, indicating that it is not yet profitable.
• The company has an accumulated deficit of $349.3 million, highlighting the extent of past losses.

Risks

• The company is an early-stage life sciences technology company with a history of net losses, which are expected to continue.
• The company has a limited operating history, making it difficult to evaluate its current business and future prospects.
• The company's operating results may fluctuate significantly in the future, making future results difficult to predict.
• The size of the markets for the Proteograph Product Suite may be smaller than estimated, limiting the company's ability to sell its products.
• The company is in the early stages of commercialization and may not be able to commercialize the Proteograph Product Suite as planned.
• The company's commercial success depends on broad scientific and market acceptance of the Proteograph, which may not be achieved.
• The company relies on single suppliers for some components of the Proteograph Product Suite, which could disrupt supply if these suppliers fail.
• The company's products could have defects or errors, which may give rise to claims against the company and adversely affect market adoption.
• The company may need to raise additional capital in the future, which may not be available on favorable terms or at all.
• The company may be subject to claims challenging the inventorship of its patents and other intellectual property.

Future Outlook

The company expects to continue to incur significant losses and does not expect positive cash flows from operations for the foreseeable future. However, based on its cash, cash equivalents, and investments, the company believes it will have adequate liquidity over the next twelve months to operate its business and meet its cash requirements.

Management Comments

• Management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth.
• The Company believes that its cash and cash equivalents and investments as of June 30, 2024 provide sufficient capital resources to continue its operations for at least twelve months from the issuance date of the accompanying unaudited condensed consolidated financial statements.

Industry Context

The announcement reflects the challenges faced by early-stage life sciences companies in commercializing new technologies. The decrease in revenue and continued net losses are not uncommon in this sector, as companies invest heavily in research and development and build their commercial infrastructure. The company's focus on expanding its sales channels and building manufacturing capabilities is consistent with the growth strategies of other companies in the proteomics and genomics space.

Comparison to Industry Standards

• Compared to companies like Nautilus Biotechnology, Olink Proteomics, Quanterix, Quantum-Si and Standard BioTools, Seer is in a similar stage of commercialization, facing challenges in scaling revenue and achieving profitability.
• The decrease in revenue and continued net losses are consistent with the financial performance of other early-stage life sciences companies that are still in the process of establishing market presence and adoption of their technologies.
• The company's focus on expanding its sales channels and building manufacturing capabilities is consistent with the growth strategies of other companies in the proteomics and genomics space.
• The company's cash position of $344.6 million is relatively strong compared to some of its peers, providing a buffer for continued operations and investments.

Legal Proceedings

• The company had accrued legal contingencies of $1.3 million as of June 30, 2024.
• The company is involved in a lawsuit filed by Giulio Caracciolo and Dipartimento di Medicina Molecolare Sapienza Universita di Roma alleging wrongful exclusion as an inventor on certain patents.

Related Party Transactions

• The company recognized revenue from a related party, PrognomiQ, Inc., that represented 19% and 25% of total revenue for the three and six months ended June 30, 2024, respectively.
• As of June 30, 2024, the company recorded $0.6 million in related party receivables, mainly due from product sales to PrognomiQ.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and continued net losses.
• Employees may be affected by the company's strategic realignment and cost-saving measures.
• Customers may be impacted by the company's ability to deliver products and services on a timely basis.
• Suppliers may be affected by the company's financial performance and ability to meet its obligations.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will continue to focus on commercializing the Proteograph Product Suite.
• The company will continue to build its sales, marketing, service, support, and distribution infrastructure.
• The company will continue to engage in research and development of other products and enhancements to the Proteograph Product Suite.
• The company will continue to build out and expand its in-house NP manufacturing capabilities.

Key Dates

Keywords

Proteomics, Proteograph Product Suite, Life Sciences, Financial Results, Revenue, Net Loss, Commercialization, Research and Development, Share Repurchase, Investments